menu
    • menu
    [{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JMB-2002","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Not Applicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JMB2002","moa":"Spike glycoproteins of mutant viruse","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Not Applicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JMB2002","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Not Applicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0.65000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Jemincare \/ Orion","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion"},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"JMKX003801","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Jemincare

    Menu

    Jemincare

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMKX003801

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

                            Details : JMKX003801 is a novel small molecule drug which is being evaluated in preclinical studies for the treatment of infection caused by Gram-negative bacteria.

                            Brand Name : JMKX003801

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 26, 2023

                            Lead Product(s) : JMKX003801

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMKX002992

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Genentech

                            Deal Size : $650.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androge...

                            Details : Under the terms of the agreement, Genentech will be granted an exclusive license to develop and commercialize the JMKX002992 worldwide, and will be fully responsible for the development and commercialization costs.

                            Brand Name : JMKX002992

                            Molecule Type : Small molecule

                            Upfront Cash : $60.0 million

                            August 18, 2022

                            Lead Product(s) : JMKX002992

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Genentech

                            Deal Size : $650.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMKX000623

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Orion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Orion Enters Into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for The Treatment of ...

                            Details : According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.

                            Brand Name : JMKX000623

                            Molecule Type : Small molecule

                            Upfront Cash : $15.8 million

                            May 06, 2022

                            Lead Product(s) : JMKX000623

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Orion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMKX000623

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Orion and Jemincare Enter Into an Exclusive Agreement Regarding a Non-Opioid Drug Candidate for The Treatment ...

                            Details : According to the agreement, Orion has the right to develop and commercialize the drug precursor in its own territory. JMKX000623 is a potent and selective Nav1.8 blocker independently developed by Jemincare.

                            Brand Name : JMKX000623

                            Molecule Type : Small molecule

                            Upfront Cash : $16.1 million

                            May 06, 2022

                            Lead Product(s) : JMKX000623

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMB2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jemincare Group Has Completed the Phase I Clinical Trial of its anti-SARS-CoV-2 Neutralizing Antibody JMB2002

                            Details : The clinical trial of JMB2002 was a single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial was designed to evaluate JMB2002's tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy s...

                            Brand Name : JMB2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 13, 2021

                            Lead Product(s) : JMB2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMB2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

                            Details : JMB2002 can precisely occupy the key epitope of the receptor binding domain on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II binding interface, and has strong binding and blocking activities to the spike glycoproteins of mu...

                            Brand Name : JMB2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 02, 2021

                            Lead Product(s) : JMB2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed

                            Jemincare

                            China arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMB-2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jemincare Initiates Phase I Clinical Trial of anti-SARS-CoV-2 Neutralizing Antibody JMB2002

                            Details : Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed. In early studies, it was found that JMB2002 could effectively neutralize live virus infection ...

                            Brand Name : JMB-2002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 20, 2021

                            Lead Product(s) : JMB-2002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth